Posted 23rd August 2019 by Jane Williams
The Microbiome & Probiotics Series: Europe is one of the highlights of our calendar year. Kristin Neumann, author & founder of MyMicrobiome was one of our speakers on the cosmeceuticals track and was kind enough to write the following recap of the event, for people who weren’t able to attend this year. You can read the original article here.
Posted 19th August 2019 by Jane Williams
e-Therapeutics, an Oxford-based company, is using its network-driven drug discovery (NDD) technology to embrace the inherent complexity of biology, providing a novel and productive method for the discovery of new medicines.
Jonny Wray is the head of Discovery Informatics at e-Therapeutics. Trained as a computational neuroscientist, he is responsible for building the NDD technology. We spoke to him ahead of his presentation at the Global Pharma R&D Informatics & AI Congress.
Posted 16th August 2019 by Jane Williams
Andrew Cook has worked in the pharmaceutical industry for over 20 years. Throughout his career, he has endeavoured to do things differently, a little out of the ordinary, leading him to his work at H3 Biomedicine on splice modulators. “Part of the reason it attracted me” he says, “is it’s so different. It’s a natural product-based drug discovery effort, and I had never done that before”.
Posted 12th August 2019 by Jane Williams
Gregory Maloney, Senior Scientist at Novozymes BioAg will be hosting a roundtable discussion at the Partnerships in Biocontrol, Biostimulants & Microbiome Congress: USA on navigating the regulatory landscape of biological product development. We spoke to him ahead of the congress about his work.
Posted 9th August 2019 by Jane Williams
Following the Microbiome R&D & Business Collaboration Forum, we have made the following presentation slides available from Finn Terge Hegge, Angela Sessitsch, Evelina Munukka and Jonathan de Jonge.
Posted 5th August 2019 by Jane Williams
Karl Cameron Schiller is co-founder of Pheronym, a Davis-based agriculture biotech start-up using a new kind of pheromone from microscopic roundworms called nematodes to control agricultural pests. We asked him about his work.
Posted 2nd August 2019 by Jane Williams
With a background in pharmacology, toxicology, molecular cell biology and genetics, Rangaprasad Sarangarajan joined BERG Health in 2010 as head of R&D.
In the initial years of the company, he aided in the conception, design, and implementation of the paradigm of looking at human biology, use of technology to generate molecular signatures, and the use of artificial intelligence-based analytics for understanding the complexity of biology, identifying of targets, and developing of drugs, and its utility in clinical development.
Posted 31st July 2019 by Jane Williams
Terry Stone has worked in agricultural products for almost 30 years and has experience in both research and regulatory affairs. He is currently Vice President of Regulatory Affairs and Sustainability Programs for Agrinos, where he works with industry associations in the US and the EU to develop a regulatory framework for plant biostimulants. We spoke to him about his work.